Allos Therapeutics Announces Interim Results From Phase 1 Combination Study Of FOLOTYN® And Bexarotene Demonstrate Activity In Patients With Relapsed Or Refractory Cutaneous T-cell Lymphoma
Note: The Allos logo and FOLOTYN name are registered trademarks of Allos Therapeutics, Inc.
- Cutaneous Lymphoma Foundation. Fast Facts: Cutaneous T-Cell Lymphoma. http://www.clfoundation.org/sites/default/files/content/CTCL_2011.pdf. Accessed January 24, 2012.
- Cutaneous Lymphoma Foundation. Fast Facts: Sézary Syndrome. http://www.clfoundation.org/sites/default/files/content/Fact%20Sheet_SS.pdf. Accessed January 24, 2012.
- Accessed January 24, 2012.Cutaneous Lymphoma Foundation. About Cutaneous T-Cell Lymphoma. http://www.clfoundation.org/about-cutaneous-lymphoma/who-gets-cutaneous-lymphoma-and-how-many-people-have-it. Accessed January 24, 2012.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV